Skip to main content
Quest Diagnostics

Analytical Validation of a SARS-CoV-2 Whole Genome Sequencing Method by Amplicon-Based NGS

AMP 2020: Association for Molecular Pathology Annual Meeting & Expo
Virtual [in-person conference canceled], November 16-20, 2020

Analytical validation of a SARS-CoV-2 whole genome sequencing method by amplicon-based NGS

Authors: Rosenthal SH, Kagan RH, Gerasimova A, Liu Y, Hua M, Anderson B, Catanese J, Lacbawan F, Owen R

Specialties: Infectious disease, COVID-19, Genetics

Download key summary

Related content

Publication
Coronavirus Disease 2019 (COVID-19) Real World Data Infrastructure: A Big-Data Resource for Study of the Impact of COVID-19 in Patient Populations With Immunocompromising Conditions
Publication
SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent COVID-19-Related Outcomes
Publication
Assessing vulnerability to COVID 19 in high risk populations: the role of SARS CoV 2 spike targeted serology
Test FAQ
SARS CoV 2 Antibody Testing

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.